Regional lymph node density-based nomogram predicts prognosis in nasopharyngeal carcinoma patients without distant metastases

[1] Chen YP(2019)Nasopharyngeal carcinoma The Lancet 394 64-80

[2] Chan ATC(2020)Head and Neck cancers, Version 2.2020, NCCN Clinical Practice guidelines in Oncology J Natl Compr Canc Netw 18 873-98

[3] Le QT(2021)Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II-IVA nasopharyngeal carcinoma: CSCO and ASCO guideline JCO 39 840-59

[4] Blanchard P(2005)Long-term survival after cisplatin-based induction chemotherapy and Radiotherapy for nasopharyngeal carcinoma: a Pooled Data Analysis of two phase III trials JCO 23 1118-24

[5] Sun Y(2016)Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial Lancet Oncol 17 1509-20

[6] Ma J(2015)Management of nasopharyngeal carcinoma: current practice and future perspective JCO 33 3356-64

[7] Pfister DG(2017)Validation of the 8th Edition of the UICC/AJCC staging system for nasopharyngeal carcinoma from endemic areas in the intensity-modulated radiotherapy era J Natl Compr Canc Netw 15 913-9

[8] Spencer S(2021)Comparing the 7th and 8th editions of UICC/AJCC staging system for nasopharyngeal carcinoma in the IMRT era BMC Cancer 21 327-15

[9] Adelstein D(2016)Prognostic nomogram for refining the prognostication of the proposed 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy: prognostic nomogram for nasopharyngeal cancer Cancer 122 3307-9

[10] Adkins D(2018)Comparison of the seventh and eighth editions of the UICC/AJCC staging system for nasopharyngeal carcinoma: analysis of 1317 patients treated with intensity-modulated radiotherapy at two centers BMC Cancer 18 606-30

[1] Chen YP(2019)Nasopharyngeal carcinoma The Lancet 394 64-80

[2] Chan ATC(2020)Head and Neck cancers, Version 2.2020, NCCN Clinical Practice guidelines in Oncology J Natl Compr Canc Netw 18 873-98

[3] Le QT(2021)Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II-IVA nasopharyngeal carcinoma: CSCO and ASCO guideline JCO 39 840-59

[4] Blanchard P(2005)Long-term survival after cisplatin-based induction chemotherapy and Radiotherapy for nasopharyngeal carcinoma: a Pooled Data Analysis of two phase III trials JCO 23 1118-24

[5] Sun Y(2016)Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial Lancet Oncol 17 1509-20

[6] Ma J(2015)Management of nasopharyngeal carcinoma: current practice and future perspective JCO 33 3356-64

[7] Pfister DG(2017)Validation of the 8th Edition of the UICC/AJCC staging system for nasopharyngeal carcinoma from endemic areas in the intensity-modulated radiotherapy era J Natl Compr Canc Netw 15 913-9

[8] Spencer S(2021)Comparing the 7th and 8th editions of UICC/AJCC staging system for nasopharyngeal carcinoma in the IMRT era BMC Cancer 21 327-15

[9] Adelstein D(2016)Prognostic nomogram for refining the prognostication of the proposed 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy: prognostic nomogram for nasopharyngeal cancer Cancer 122 3307-9

[10] Adkins D(2018)Comparison of the seventh and eighth editions of the UICC/AJCC staging system for nasopharyngeal carcinoma: analysis of 1317 patients treated with intensity-modulated radiotherapy at two centers BMC Cancer 18 606-30